A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

D. H. Lee; A. Roohullah; B. C. Cho; S-H. Lee; C. Lemech; P. De Souza; M. Millward; J. Choi; K. E. Park; E. Kim; N. Y. Kim; Y. K. Shin; J-Y. Han

doi:10.1016/j.annonc.2022.07.1320

A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

D. H. Lee, A. Roohullah, B. C. Cho, S-H. Lee, C. Lemech, P. De Souza, M. Millward, J. Choi, K. E. Park, E. Kim, N. Y. Kim, Y. K. Shin, J-Y. Han

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S1096-S1096
Number of pages	1
Journal	Annals of Oncology
Volume	33
Issue number	7
DOIs	https://doi.org/10.1016/j.annonc.2022.07.1320
Publication status	Published - Sept 2022
Event	2022 Annual Meeting of the European-Society-for-Medical-Oncology - , France Duration: 9 Sept 2022 → 13 Sept 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2022.07.1320

Cite this

Lee, D. H., Roohullah, A., Cho, B. C., Lee, S-H., Lemech, C., De Souza, P., Millward, M., Choi, J., Park, K. E., Kim, E., Kim, N. Y., Shin, Y. K., & Han, J-Y. (2022). A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation. Annals of Oncology, 33(7), S1096-S1096. https://doi.org/10.1016/j.annonc.2022.07.1320

Lee, D. H. ; Roohullah, A. ; Cho, B. C. et al. / A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation. In: Annals of Oncology. 2022 ; Vol. 33, No. 7. pp. S1096-S1096.

@article{58fe64fa80714350b5b09d8bcc008a01,

title = "A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation",

author = "Lee, {D. H.} and A. Roohullah and Cho, {B. C.} and S-H. Lee and C. Lemech and {De Souza}, P. and M. Millward and J. Choi and Park, {K. E.} and E. Kim and Kim, {N. Y.} and Shin, {Y. K.} and J-Y. Han",

year = "2022",

month = sep,

doi = "10.1016/j.annonc.2022.07.1320",

language = "English",

volume = "33",

pages = "S1096--S1096",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "7",

note = "2022 Annual Meeting of the European-Society-for-Medical-Oncology, ESMO 2022 ; Conference date: 09-09-2022 Through 13-09-2022",

}

Lee, DH, Roohullah, A, Cho, BC, Lee, S-H, Lemech, C, De Souza, P, Millward, M, Choi, J, Park, KE, Kim, E, Kim, NY, Shin, YK & Han, J-Y 2022, 'A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation', Annals of Oncology, vol. 33, no. 7, pp. S1096-S1096. https://doi.org/10.1016/j.annonc.2022.07.1320

A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation. / Lee, D. H.; Roohullah, A.; Cho, B. C. et al.
In: Annals of Oncology, Vol. 33, No. 7, 09.2022, p. S1096-S1096.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

AU - Lee, D. H.

AU - Roohullah, A.

AU - Cho, B. C.

AU - Lee, S-H.

AU - Lemech, C.

AU - De Souza, P.

AU - Millward, M.

AU - Choi, J.

AU - Park, K. E.

AU - Kim, E.

AU - Kim, N. Y.

AU - Shin, Y. K.

AU - Han, J-Y.

PY - 2022/9

Y1 - 2022/9

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000866211601459

U2 - 10.1016/j.annonc.2022.07.1320

DO - 10.1016/j.annonc.2022.07.1320

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 33

SP - S1096-S1096

JO - Annals of Oncology

JF - Annals of Oncology

IS - 7

T2 - 2022 Annual Meeting of the European-Society-for-Medical-Oncology

Y2 - 9 September 2022 through 13 September 2022

ER -

Lee DH, Roohullah A, Cho BC, Lee S-H, Lemech C, De Souza P et al. A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation. Annals of Oncology. 2022 Sept;33(7):S1096-S1096. doi: 10.1016/j.annonc.2022.07.1320

A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation

UN SDGs

Access to Document

Other files and links

Cite this